Nabriva Therapeutics AG 4
4 · Nabriva Therapeutics AG · Filed Jun 1, 2017
Insider Transaction Report
Form 4
Talbot George Harrison
Director
Transactions
- Sale
Common Shares
2017-05-30$101.50/sh−110$11,165→ 3,449 total - Sale
Common Shares
2017-05-30$101.00/sh−100$10,100→ 3,349 total
Footnotes (3)
- [F1]The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares.
- [F2]The price of $101.50 per common share was derived from the sale price on May 30, 2017, of $10.15 per ADS, multiplied by ten.
- [F3]The price of $101.00 per common share was derived from the sale price on May 30, 2017, of $10.10 per ADS, multiplied by ten.